Document is current

Article History

Received: 18 November 2021

Accepted: 23 May 2022

First Online: 14 June 2022

Change Date: 2 October 2022

Change Type: Update

Change Details: This article has been updated to correct the funding information.

Declarations

:

: We received approval from the ethics committee of the Hospital District of Helsinki and Uusimaa (304/13/03/03/2015). The register-keeping organizations approved the use of their register data in this study. We received a consent waiver from the ethics committee as this is a retrospective register-based cohort study. All methods were carried out in accordance with relevant guidelines and regulations and STROBE checklist was followed in reporting the study.

: Not applicable.

: The authors declare no support from any organisation for the submitted work; author TS has been paid for developing and delivering educational presentations for Bayer and Novartis companies and serves on an advisory board for Gedeon Richter, author OH serves occasionally on advisory boards for Bayer AG, Gedeon Richter, HRA-Pharma, Sandoz A/S and Vifor Pharma, and has designed and lectured at educational events of these companies; no other relationships or activities that could appear to have influenced the submitted work. All other authors have no Competing Interest to declare.